Examkin

Question

Difficulty: HardBipolar and Related Disorders

A 42-year-old male architect is brought to his primary care physician by his husband due to a 2-month history of severe depressed mood, excessive guilt, and terminal insomnia. The patient states that he has completely lost interest in his architectural projects, feels like a burden to his family, and has lost 6.8 kg (15 lb) over this period. His medical history is significant for primary hypothyroidism, which has been well-controlled on levothyroxine. Review of his past medical records reveals a prior psychiatric admission at age 26 after he spent his entire life savings on a spontaneous trip to Europe, during which he believed he was a prophet destined to unite the world. He was treated with an unknown medication and stabilized but stopped all psychiatric care a year later. His current vital signs are stable. Physical examination is unremarkable. Mental status examination reveals a disheveled appearance, marked psychomotor retardation, flat affect, and poverty of speech. He denies current suicidal ideation or auditory hallucinations. Laboratory testing demonstrates a thyroid-stimulating hormone (TSH) level of 1.8 µU/mL (normal: 0.5-5.0 µU/mL) and a free thyroxine (T4) level of 1.3 ng/dL (normal: 0.9-1.7 ng/dL). Which of the following is the most appropriate next step in pharmacotherapy?

  1. Prescribe lurasidoneAnswer
  2. B
    Prescribe sertraline
  3. C
    Increase the levothyroxine dosage
  4. D
    Prescribe phenelzine and citalopram
  5. E
    Prescribe haloperidol

Answer

Prescribe lurasidone
This patient presents with a severe major depressive episode (depressed mood, anhedonia, weight loss, terminal insomnia, guilt, psychomotor retardation). Crucially, his history of a severe mood episode at age 26 involving reckless spending, delusions of being a prophet, and hospitalization is diagnostic of a manic episode with psychotic features. Therefore, his correct diagnosis is bipolar I disorder, currently in a depressed episode. The first-line pharmacological treatment for acute bipolar depression includes specific second-generation antipsychotics, notably lurasidone, quetiapine, or cariprazine. Lurasidone is highly effective for bipolar depression and has a favorable metabolic profile. Antidepressant monotherapy must be avoided due to the high risk of precipitating mania.

Step-by-Step Solution

1
Identify the patient's current clinical presentation.
The patient is experiencing a major depressive episode, characterized by a 2-month history of depressed mood, anhedonia, significant weight loss, terminal insomnia, guilt, and psychomotor retardation.
Establishing the current mood episode is necessary to guide acute management.
2
Review the patient's past psychiatric and medical history.
The patient has a history of an episode at age 26 involving grandiosity, delusions, impulsive spending, and hospitalization, which meets the criteria for a manic episode with psychotic features. His thyroid function tests are currently normal.
A history of mania changes the diagnosis from major depressive disorder to bipolar I disorder, fundamentally altering the treatment algorithm. Normal thyroid labs rule out a medical cause for his depression.
3
Determine the most appropriate pharmacotherapy for acute bipolar depression.
First-line monotherapy options for bipolar depression include lurasidone, quetiapine, and cariprazine.
These atypical antipsychotics treat depressive symptoms in bipolar disorder without carrying the risk of precipitating a manic switch, unlike standard antidepressant monotherapy.

Key Concept

The diagnosis of bipolar I disorder requires a history of at least one manic episode; current depressive episodes must be treated with specific atypical antipsychotics (e.g., lurasidone, quetiapine, cariprazine) or mood stabilizers while avoiding antidepressant monotherapy.
Rate this question

Topics

Bipolar and Related Disorders

More questions from this topic